BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 36825574)

  • 1. Screening for DAX1/EWS-FLI1 functional inhibitors identified dihydroorotate dehydrogenase as a therapeutic target for Ewing's sarcoma.
    Watanabe M; Kosaka H; Sugawara M; Maemoto M; Ono Y; Uemori T; Shizu R; Yoshinari K
    Cancer Med; 2023 Apr; 12(8):9802-9814. PubMed ID: 36825574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A zebrafish transgenic model of Ewing's sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis.
    Leacock SW; Basse AN; Chandler GL; Kirk AM; Rakheja D; Amatruda JF
    Dis Model Mech; 2012 Jan; 5(1):95-106. PubMed ID: 21979944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma.
    Boro A; Prêtre K; Rechfeld F; Thalhammer V; Oesch S; Wachtel M; Schäfer BW; Niggli FK
    Int J Cancer; 2012 Nov; 131(9):2153-64. PubMed ID: 22323082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Junction region of EWS-FLI1 fusion protein has a dominant negative effect in Ewing's sarcoma in vitro.
    Jully B; Vijayalakshmi R; Gopal G; Sabitha K; Rajkumar T
    BMC Cancer; 2012 Nov; 12():513. PubMed ID: 23145994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The evaluation of CD99 immunoreactivity and EWS/FLI1 translocation by fluorescence in situ hybridization in central PNETs and Ewing's sarcoma family of tumors.
    Vural C; Uluoğlu O; Akyürek N; Oğuz A; Karadeniz C
    Pathol Oncol Res; 2011 Sep; 17(3):619-25. PubMed ID: 21267687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A polypeptide from the junction region sequence of EWS-FLI1 inhibits Ewing's sarcoma cells, interacts with the EWS-FLI1 and partner proteins.
    Thangaretnam KP; Gopisetty G; Ramanathan P; Rajkumar T
    Sci Rep; 2017 Aug; 7(1):7172. PubMed ID: 28775288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma.
    Kinsey M; Smith R; Iyer AK; McCabe ER; Lessnick SL
    Cancer Res; 2009 Dec; 69(23):9047-55. PubMed ID: 19920188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells.
    García-Aragoncillo E; Carrillo J; Lalli E; Agra N; Gómez-López G; Pestaña A; Alonso J
    Oncogene; 2008 Oct; 27(46):6034-43. PubMed ID: 18591936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOXO1 is a direct target of EWS-Fli1 oncogenic fusion protein in Ewing's sarcoma cells.
    Yang L; Hu HM; Zielinska-Kwiatkowska A; Chansky HA
    Biochem Biophys Res Commun; 2010 Nov; 402(1):129-34. PubMed ID: 20933505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma.
    Ban J; Jug G; Mestdagh P; Schwentner R; Kauer M; Aryee DN; Schaefer KL; Nakatani F; Scotlandi K; Reiter M; Strunk D; Speleman F; Vandesompele J; Kovar H
    Oncogene; 2011 May; 30(18):2173-80. PubMed ID: 21217773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The orphan nuclear receptor DAX1 is up-regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors.
    Mendiola M; Carrillo J; García E; Lalli E; Hernández T; de Alava E; Tirode F; Delattre O; García-Miguel P; López-Barea F; Pestaña A; Alonso J
    Int J Cancer; 2006 Mar; 118(6):1381-9. PubMed ID: 16206264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dual inhibitory effect of thiostrepton on FoxM1 and EWS/FLI1 provides a novel therapeutic option for Ewing's sarcoma.
    Sengupta A; Rahman M; Mateo-Lozano S; Tirado OM; Notario V
    Int J Oncol; 2013 Sep; 43(3):803-12. PubMed ID: 23857410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition.
    Awad O; Yustein JT; Shah P; Gul N; Katuri V; O'Neill A; Kong Y; Brown ML; Toretsky JA; Loeb DM
    PLoS One; 2010 Nov; 5(11):e13943. PubMed ID: 21085683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma.
    Rao DD; Jay C; Wang Z; Luo X; Kumar P; Eysenbach H; Ghisoli M; Senzer N; Nemunaitis J
    Mol Ther; 2016 Aug; 24(8):1412-22. PubMed ID: 27166877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway.
    Ren C; Ren T; Yang K; Wang S; Bao X; Zhang F; Guo W
    J Exp Clin Cancer Res; 2016 Mar; 35():44. PubMed ID: 26969300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ewing's sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent.
    Uren A; Toretsky JA
    Future Oncol; 2005 Aug; 1(4):521-8. PubMed ID: 16556028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the oncogenic fusion protein EWS-FLI1 causes G
    Zöllner SK; Selvanathan SP; Graham GT; Commins RMT; Hong SH; Moseley E; Parks S; Haladyna JN; Erkizan HV; Dirksen U; Hogarty MD; Üren A; Toretsky JA
    Sci Signal; 2017 Oct; 10(499):. PubMed ID: 28974650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening.
    Grohar PJ; Woldemichael GM; Griffin LB; Mendoza A; Chen QR; Yeung C; Currier DG; Davis S; Khanna C; Khan J; McMahon JB; Helman LJ
    J Natl Cancer Inst; 2011 Jun; 103(12):962-78. PubMed ID: 21653923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma.
    Kinsey M; Smith R; Lessnick SL
    Mol Cancer Res; 2006 Nov; 4(11):851-9. PubMed ID: 17114343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. O-GlcNAcylation is involved in the transcriptional activity of EWS-FLI1 in Ewing's sarcoma.
    Bachmaier R; Aryee DN; Jug G; Kauer M; Kreppel M; Lee KA; Kovar H
    Oncogene; 2009 Mar; 28(9):1280-4. PubMed ID: 19151750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.